Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1.
Effect of topical treatments with BV-araU was tested in cutaneous infections of shaved Balb/c mice with herpes simplex virus type 1. Evolution of zosteriform skin lesions associated with infection with a low virulent KOS(S) strain was almost completely suppressed by treatments with 5% BV-araU cream given 4 times daily for 5 days starting 1 day after inoculation. This effect was equivalent to that of Zovirax Cream including 5% acyclovir. One percent BV-araU cream was also effective in inhibiting progression of symptoms, while 0.2% cream was not effective. Five percent BV-araU cream significantly suppressed progression of skin lesion even if initiation of treatment was delayed to 2 days after infection. However, the efficacy was diminished by further delay in starting treatment. The effect of BV-araU cream was also evident during infection of immunosuppressed mice. Virus titers in the skin tissue encompassing the inoculation site of mice decreased the day after the first treatment. In the lower flank site, virus replication was almost completely suppressed by the treatment beginning 1 day postinfection. Topical application of BV-araU may be useful therapy for HSV-1 infections in humans, including immunocompromised patients.
Ijichi
K
K
Biology Laboratory, Yamasa Corporation, Choshi, Japan.
Ashida
N
N
Varia
S
S
Machida
H
H
D000287:Administration, Topical; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000494:pharmacology; D003520:Cyclophosphamide; D004305:Dose-Response Relationship, Drug; D006561:Herpes Simplex / Q000188:drug therapy* / Q000276:immunology; D007108:Immune Tolerance / Q000502:physiology*; D007121:Immunocompetence / Q000502:physiology*; D016867:Immunocompromised Host / Q000502:physiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018139:Simplexvirus / Q000187:drug effects / Q000254:growth & development; D017193:Skin Diseases, Viral / Q000188:drug therapy* / Q000276:immunology; D013997:Time Factors
D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; D003520:Cyclophosphamide; C031368:sorivudine